TPG
PYPL
ALLO

Deborah M. Messemer

Known title: DirectorCIK: 0001754424

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 17, 2026

TPG Shares Drop Amid Sector Weakness; Analyst Cuts Target to $60. TPG shares fell recently alongside other financial names, reflecting broader market pressure. TD Cowen maintained its positive stance but lowered its price target to $60, citing current market conditions. The stock is trading below its average analyst target, with technical indicators showing it is testing key support levels.

this person other insiders at TPG

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 17, 2026

PayPal (PYPL) launches AI-powered checkout with Glance. PayPal announced an AI-driven shopping and checkout experience in partnership with Glance, bringing the technology to tens of millions of U.S. consumers. The rollout is described as the company's first major AI commerce initiative and is expected to enhance merchant and buyer interactions. Recent coverage notes that PayPal outperformed the broader market and that Bank of America has resumed payments sector coverage, highlighting renewed analyst focus on the firm.

this person other insiders at PYPL

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

September 7, 2026

Allogene CFO Departure Comes Amid CAR-T Sector Safety Concerns. Allogene announced that Chief Financial Officer Geoffrey Parker will retire effective November 6, marking a leadership transition at a challenging time for the company. The timing coincides with broader scrutiny of CAR-T therapies for autoimmune conditions after competing trials from Novartis and Bristol Myers were paused over safety concerns. On the clinical front, the company indicated that if its minimal residual disease data holds, it could represent a significant shift in its business outlook. The stock has traded within a $1.04 to $4.46 range over the past year.

this person other insiders at ALLO

Transaction History

TPG▲ Buy—
PYPL▲ Buy$0
TPG▼ Sell$101K
TPG▲ Buy—
ALLO▼ Sell$52K
PYPL▼ Sell$277K
PYPL▲ Buy$0
ALLO▼ Sell$32K
TPG▼ Sell$105K
ALLO▼ Sell$20K
TPG▼ Sell$190K
TPG▲ Buy—
ALLO▼ Sell$42K
ALLO▲ Buy$0
PYPL▼ Sell$273K
PYPL▲ Buy$0
TPG▼ Sell$281K
ALLO▼ Sell$50K
TPG▲ Buy—
ALLO▲ Buy$0
PYPL▲ Buy$0
TPG▲ Buy—
PYPL▲ Buy$0
TPG▲ Buy—

We use analytics to understand how market-wall is used. No personal data is sold.